Taysha Gene Therapies Issues Equity Grants to Four New Hires
Taysha granted RSUs and stock options to four new employees under its 2023 Inducement Plan, totaling 476,400 shares.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) disclosed Thursday that its Compensation Committee approved equity awards for four newly hired employees, effective October 1, 2026, under a standard Nasdaq inducement-grant provision designed to attract talent without requiring shareholder approval.
The awards consist of restricted stock units representing 384,000 shares of common stock and a stock option covering 92,400 shares, all issued pursuant to the company's 2023 Inducement Plan. The grants comply with Nasdaq Listing Rule 5635(c)(4), which permits equity compensation to new employees as a material inducement to accepting a position.
Read more Xryma Plc Reports Resignation of Independent Non-Executive Directors →
Dallas-based Taysha focuses on developing adeno-associated virus gene therapies targeting severe monogenic diseases of the central nervous system. The company is in the clinical stage, meaning it has not yet brought a product to market and relies on capital markets and strategic hires to advance its pipeline.
Inducement grants are a common tool among clinical-stage biotechs competing for specialized scientific and operational talent. By structuring awards under a dedicated inducement plan, companies preserve shares in their primary equity pool while still offering competitive compensation packages to incoming personnel.
Continue reading at GlobeNewswire - Industry News on Financial Services
